RFK Jr. issued the notice after FDA outside advisers backed the six peptides in a contested July recommendation, BioPharma Dive reports.
Recap by typeshit. Full story at BioPharma Dive.
The peptide item sits among gene therapy, Neuralink and Medicare news. The Alliance for Safe Biologic Medicines has asked HHS to pause the policy, citing FDA scientists.
Maria David Patten alleges Novo hid NAION risks; her case joins the federal MDL before Judge Karen Marston in Pennsylvania, where bellwether trials are expected.
HHS now lets pharmacies compound BPC-157, TB-500 and four others, but BoxingInsider notes all six remain on WADA's banned list for licensed boxers.
Politico looks at the warning signs around Health Secretary Kennedy's move to let six peptides that lack FDA approval reach the US market.
Q3 revenue hit $24.40 billion, up 39% from a year ago. China's reimbursement listing for Mounjaro helped drive international demand.
The first four weeks cost around 129,800 won at supply price. Hanmi reports 9.75% average weight loss over 40 weeks and has set a 100 billion won first-year sales target.
Loading…